Anti Inflammatory and Analgesic Effect of Ginger Powder in Dental Pain Model

Summary

Ginger contains constituents with pharmacological properties similar to the novel class of dual-acting NSAIDs. Compounds in this class inhibit arachidonic acid metabolism via the cyclooxygenase (COX) and lipooxygenase (LOX) pathways. These compounds have notably fewer side effects than conventional NSAIDs and now are being investigated as a novel class of anti-inflammatory compounds. Although ginger has potentially strong anti-inflammatory components, its efficacy on acute inflammation was not assessed before. The common postoperative sequelae of surgical removal of impacted teeth are pain, trismus and swelling, related to local inflammatory reaction, with cyclooxygenase and prostaglandins playing a crucial role. NSAIDs (e.g. Ibuprofen) are effective in the management of postoperative dental pain, likely through blockage of prostaglandin synthesis and are commonly used. The efficacy of Ibuprofen in the treatment of postoperative dental pain has been evaluated in several clinical trials. However, NSAIDs are contraindicated in patients with gastrointestinal ulcers, bleeding disorders, and renal dysfunctions. Therefore, there is a need for an effective, oral analgesic with a more favorable safety profile. The primary aim of this study was to investigate the ability of Ginger powder (Zintoma, Goldaru) to reduce postoperative swelling, pain and trismus in an acute pain model.

Conditions

• Impacted Third Molar Tooth

Interventions

DRUG

Ginger powder

capsules contain 500mg Ginger powder,every 6hours,for 5 days

DRUG

Ibuprofen

capsules of Ibuprofen 400 mg, every 6 hours for 5 days

OTHER

placebo

capsules contain starch

Sponsors & Collaborators

• Qazvin University Of Medical Sciences

  lead OTHER

Principal Investigators

• Farshid Rayati, DDS,OMFS · Assisstant professor of oral and maxillofacial dapartment

• Fateme Hajmanuchehri · Assisstant professor of general pathology department

• Mehran Purghasemi · General pharmacologist

• Elnaz Najafi, DDS · General dentist

• Farshid Rayati, DDS,OMFS · Assisstant professor of oral and maxillofacial department

• Elanaz Najafi, dentist · General dentist

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

40 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2010-06-30

Primary Completion

2011-09-30

Completion

2011-10-31

Countries

• Iran

Study Locations